Organization (Industry)
ARTIVION, INC.
ClinicalTrials.gov lists ARTIVION, INC. as lead sponsor of 33 trials, counting the companies grouped under it. ARTIVION, INC. itself has 3 active development programs and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers ARTIVION, INC. and 3 companies grouped under it: 33 lead-sponsored trials (7 its own, 26 in the grouped companies) and 3 legal-entity registrations (2 its own, 1 in the grouped companies).
Companies grouped under this page (3)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| JOTEC GmbH | 20 | 1 |
| On-X Life Technologies, Inc. | 4 | 0 |
| Ascyrus Medical LLC. | 2 | 0 |
Disease areas (33)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Aortic Aneurysm | 7 |
| Aortic Dissection | 7 |
| Aortic Aneurysm, Abdominal | 3 |
| Aortic Valve Stenosis | 3 |
| Hemorrhage | 3 |
Showing 5 of 33 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2022 | 2 |
| 2020 | 1 |
| 2018 | 2 |
| 2017 | 4 |
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 2 |
Showing 10 of 13 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (3)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Apixaban 2.5 MG | Aortic Valve Stenosis | Phase 3 | 1 |
| Apixaban 5 MG | Aortic Valve Stenosis | Phase 3 | 1 |
| Sodium warfarin | Aortic Valve Stenosis | Phase 3 | 1 |
Approved assets (1)
| Drug | Trials |
|---|---|
| Sodium warfarin | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 44% hit target (n=9) | 33% on time (n=9) |
Journals published in (34)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Annals of thoracic surgery | 9 |
| The Journal of thoracic and cardiovascular surgery | 9 |
| Journal of vascular surgery | 8 |
| European heart journal | 4 |
| Annals of vascular surgery | 3 |
Showing 5 of 34 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 84 | 7 | 2025-10-21 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 441,330,000 | 9,768,000 | 30,991,000 |
| 2024 | 388,537,000 | -13,359,000 | 28,452,000 |
| 2023 | 354,004,000 | -30,690,000 | 28,707,000 |
| 2022 | 313,789,000 | -19,192,000 | 38,879,000 |
| 2021 | 298,836,000 | -14,834,000 | 35,546,000 |
| 2020 | 253,227,000 | -16,682,000 | 24,207,000 |
| 2019 | 276,222,000 | 1,720,000 | 22,960,000 |
| 2018 | 262,841,000 | -2,840,000 | 23,098,000 |
| 2017 | 189,702,000 | 3,704,000 | 19,461,000 |
| 2016 | 180,380,000 | 10,778,000 | 13,446,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (24)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-09-12 | Debt financing | not disclosed | Sec extracted |
| 2026-05-18 | Other financing | not disclosed | Sec extracted |
| 2026-05-07 | Other financing | not disclosed | Sec extracted |
| 2025-09-12 | Debt financing | not disclosed | Sec extracted |
| 2025-09-12 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 24 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 13 |
FDA recalls (3)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| CryoValve SG Pulmonary Human Heart Valve, SGPV00, Cryopreserved Decellularized Heart Valve Allograft Prepared with SynerGraft (SG) Technology. | Class II | 2024-05-28 |
| (1) CryoPatch SG Pulmonary Human Cardiac Hemi-Artery - Artery Patch, SGPH00 Cryopreserved Decellularized Cardiac Tissue Allograft Prepared with SynerGraft (SG) Technology; and (2) CryoPatch SG Pulmonary Human Cardiac Branch Patch, SGP020, Cryopreserved Decellularized Cardiac Tissue Allograft Prepared with SynerGraft (SG) Technology. | Class II | 2024-05-28 |
| CryoValve SG Cryopreserved Pulmonary Human Heart Valve | Class II | 2024-03-06 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 2 | 2025-09-04 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Artivion, Inc. | Kennesaw, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Icon Plc | Uses vendor | 1 |
| Syneos Health (United States) | Uses vendor | 1 |
Latest dated events (171)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-12 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-18 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05-07 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 171 events.
Biomarker capability evidence (13)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CLU | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial exclusion criteria |
| ALB | Trial sponsor | Named in trial exclusion criteria |
| CD4 | Trial collaborator | Named in trial exclusion criteria |
| CYP3A4 | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 13 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda untitled letters, clia clinical laboratory certificates, and biomarkers this organization publishes on.